Cypress

Researchers are studying the safety and effectiveness of UBT251 for people living with overweight or obesity. This clinical trial is a phase 2 study that compares different doses of UBT251 against a placebo, which contains no active medicine. The goal is to understand how UBT251 affects body weight and tolerability in adults with these conditions. Participants will be randomly assigned to receive various doses of UBT251 or a placebo, all given as injections under the skin of the abdomen. The study includes multiple parts where participants receive different dose levels, with some receiving a single dose and others multiple doses. Placebo injections are designed to look like UBT251 to maintain study blinding. During the trial, participants will be monitored for treatment-emergent adverse events and changes in body weight over several weeks. Blood samples will be taken to measure UBT251 levels in the body. The study involves regular visits for assessments including physical exams, vital signs, and lab tests, extending up to 33 weeks. Researchers will track safety, tolerability, and how the drug moves through the body to evaluate outcomes.

Researchers are studying how well the combination of MET233 and MET097 works to treat adults who are overweight or have obesity, including some with type 2 diabetes. This is a randomized, placebo-controlled, double-blind study focusing on safety, tolerability, and how the drugs behave in the body. The study includes adults with a body mass index BMI between 27 and 45 kgm2, with certain parts including participants with type 2 diabetes. The study has several parts A, B, C, D, E, and G with different dosing schedules. Participants receive subcutaneous under the skin doses of MET233 combined with MET097 or a matching placebo. Some parts involve single ascending doses, others multiple weekly or monthly doses. After each treatment phase, there is a safety follow-up period lasting from about 12 weeks up to 11 weeks depending on the part. Participants will be monitored through scheduled visits including physical exams, lab tests, ECGs, and assessments of body weight changes. Researchers will track treatment-emergent adverse events and measure drug concentrations in the blood after dosing. The total study participation varies by part but includes screening, treatment doses, and extended safety follow-up periods. Participants need to comply with all study procedures and assessments throughout the study.

Researchers are conducting a Phase 1 clinical trial to study SPY002-072, focusing on its safety, tolerability, and how the body processes this drug in healthy adult volunteers. This first-in-human, randomized, double-blind, placebo-controlled study aims to gather important early data on SPY002-072 by comparing it to a placebo. The study is led by Spyre Therapeutics, Inc. and involves healthy men and women aged 18 to 60 years. Participants will receive a single dose of SPY002-072 or a placebo in a dose escalation format, meaning different groups will receive increasing doses to evaluate safety and drug behavior at various levels. The study design includes randomized assignment to either the drug or placebo group, with neither participants nor researchers knowing which treatment any individual receives, to ensure unbiased results. During the study, participants will attend visits at the clinical research unit and remain confined there for a period to allow close monitoring. They will undergo various tests to track any treatment-related side effects, as well as measurements of drug concentration over time, including peak levels and half-life. Follow-up visits will continue for up to 40 weeks to assess safety and drug behavior. Participants will be carefully observed for any adverse events throughout the study period.

Researchers are evaluating how the drug emraclidine, taken orally, moves through the bodies of healthy elderly adults aged 65 to 85. This Phase 1 study aims to assess the safety, tolerability, and any adverse events related to emraclidine. Participants are healthy volunteers without significant medical conditions, providing important information about how the drug behaves in older adults. Participants will receive oral doses of either emraclidine or a placebo for periods of 10 or 17 days. The study uses a randomized, placebo-controlled design with multiple ascending oral doses to compare how the drug and placebo affect the body. The treatment groups receive the study medication or placebo under close monitoring during these dosing periods. During the study, participants will undergo various assessments including medical history reviews, physical exams, vital signs, electrocardiograms ECGs, and lab tests. Researchers will track adverse events and changes in clinical measures such as movement scales and suicide risk rating scales up to approximately 20 to 50 days. Blood samples will be collected to measure drug levels and how the body processes emraclidine. Overall participation involves careful safety monitoring and evaluation of how the drug is tolerated in healthy elderly adults.

Researchers are studying how the length of fasting and temporarily stopping certain diabetes medicines called Glucagon-Like-Peptide 1 GLP-1 receptor agonists affect the amount of food remaining in the stomach. The study focuses on people who use liraglutide injected, oral semaglutide, or injected semaglutide to understand differences in stomach emptying. Participants involvement length depends on which GLP-1 medication they are currently using. Participants will be assigned to receive one of three treatments liraglutide injected under the skin once daily, oral semaglutide taken once daily, or semaglutide injected once weekly. The study evaluates stomach emptying after fasting following either a solid high-fat meal or a liquid meal, with measurements taken at multiple times after fasting begins. The study lasts up to approximately 178 days depending on the medication group. During the study, participants will undergo assessments including gastric ultrasound to check stomach contents at several time points after fasting. Researchers will measure if the stomach is empty or contains solids, as well as the volume of gastric contents. These evaluations occur at specific visits over the study period. The goal is to better understand the effects of fasting duration and pausing medication on stomach emptying in people using these diabetes treatments.

Researchers are studying the safety and how the body processes the drug SBS-147 in healthy adults aged 18 to 55 years. This Phase 1 trial is part of the HEAL Initiative and aims to identify any side effects when taking SBS-147 compared to a placebo. The study includes participants who do not have major health issues and are willing to follow study procedures. Participants are divided into two groups one group receives a single dose of SBS-147 or placebo, and the other group receives SBS-147 or placebo once or twice daily for 7 days. Those in the single-dose group stay in the clinic for 5 days, while those in the multiple-dose group stay for 10 days. Both groups complete an end-of-study visit, either on Day 8 or Day 14 depending on the dosing schedule. During the study, participants will have tests, blood draws, and questionnaires to monitor their health and how their body handles the drug. Researchers will watch for treatment-related side effects using specific criteria over 8 or 14 days. The study also measures how much SBS-147 and related substances are in the blood over time. Participants must be available for the full duration of the study and comply with all study procedures.